ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,878Medicare Part D Prescriptions Filled, Including Refills

Rank: 46 out of 254

$649K Total Retail Price of All Prescriptions

Rank: 48 out of 254

773 Patients Receiving at Least One Drug in Part D
79% Patients 65 Years and Older
70% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in New York
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

15% of this provider’s 773 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

4% of this provider’s 773 patients filled at least one prescription for a schedule three drug, compared to an average of 3%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$60 was the average price of a prescription from this provider, compared to $57 among peers.

Prescriptions per Patient

14 is the average number of prescriptions (including refills) per patient, compared to an average of 24.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in New York
SIMVASTATIN 435 316 118 1 1
FUROSEMIDE 402 355 110 2 3
LEVOTHYROXINE SODIUM 378 299 101 3 4
OMEPRAZOLE 351 204 84 4 6
AMLODIPINE BESYLATE 343 297 97 5 2
METOPROLOL TARTRATE 300 253 101 6 5
LISINOPRIL 250 220 76 7 7
ATORVASTATIN CALCIUM 209 187 53 8 9
POTASSIUM CHLORIDE 197 164 50 9 23
WARFARIN SODIUM 189 184* 47 10 8
METOPROLOL SUCCINATE 184 166 52 11 11
CITALOPRAM HBR 164 140 40 12 21
CLOPIDOGREL 151 132 45 13 18
OXYCODONE-ACETAMINOPHEN 149 101 71 S2 14 82
METFORMIN HCL 143 126 52 15 10
ALENDRONATE SODIUM 142 90 26 16 26
DONEPEZIL HCL 135 135 38 17 12
HYDROCHLOROTHIAZIDE 133 117 47 18 16
GABAPENTIN 132 92 41 19 15
DIOVAN 121 94 24 20 33
ALPRAZOLAM 118 87 44 B 21 67
ZOLPIDEM TARTRATE 116 70 38 22 36
SERTRALINE HCL 116 111* 32 22 20
PREDNISONE 108 91 57 24 41
TAMSULOSIN HCL 104 99* 22 25 19
CARVEDILOL 98 83 30 26 25
JANUVIA 91 76 23 27 28
FAMOTIDINE* 90 50 24 28 51
MIRTAZAPINE 86 81* 26 29 14
SPIRONOLACTONE 84 71 15 30 78
LOSARTAN POTASSIUM 79 79 28 31 17
PRAVASTATIN SODIUM 77 66 28 32 46
CIPROFLOXACIN HCL 75 59 49 33 71
PANTOPRAZOLE SODIUM 73 57 34 34 38
POLYETHYLENE GLYCOL 3350 72 25 19 35 40
AZITHROMYCIN 71 42 60 36 80
FLUTICASONE PROPIONATE 70 46 52 37 57
OXYBUTYNIN CHLORIDE ER 69 35 12 38 140
LANTUS 68 56 30 39 34
MONTELUKAST SODIUM 67 42 16 40 54
NOVOLOG 65 52 26 41 87
ISOSORBIDE MONONITRATE ER 64 59* 21 42 43
IPRATROPIUM-ALBUTEROL 59 54* 19 43 42
NAMENDA 58 53* 14 44 13
CYMBALTA 56 42 18 45 29
ALBUTEROL SULFATE 55 41 20 46 59
FINASTERIDE 54 54 12 47 49
PAROXETINE HCL 53 41 17 48 84
TRAMADOL HCL 53 48* 33 48 70
NEXIUM 52 <11 <11 50 32
RAMIPRIL 51 51 14 51 58
RANITIDINE HCL 50 <11 <11 52 37
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 4, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.